<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01428986</url>
  </required_header>
  <id_info>
    <org_study_id>FWA00005823-MVCBone2009</org_study_id>
    <secondary_id>UMIN000006266</secondary_id>
    <nct_id>NCT01428986</nct_id>
  </id_info>
  <brief_title>Safety Study of Maraviroc's Effect on Human Osteoclasts</brief_title>
  <acronym>MVC-Bone</acronym>
  <official_title>Safety Study of Maraviroc's Effect on Human Osteoclasts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Global Health and Medicine, Japan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Center for Global Health and Medicine, Japan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate the safety of maraviroc by examining whether there is bone
      metabolism dysfunction in actual use of maraviroc in human body, or not, measuring bone
      mineral density and markers for bone formation, desorption and chemokine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An observational study to investigate the safety of maraviroc by examining whether there is
      bone metabolism dysfunction in actual use of maraviroc in human body, or not, measuring bone
      mineral density and markers for bone formation, desorption and chemokine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of maraviroc's effect to bone metabolism and bone mineral density</measure>
    <time_frame>78 weeks</time_frame>
    <description>Follow up HIV infected patients who take maraviroc for their bone mineral density by DEXA and for following blood/urine markers of bone metabolism and chemokine for 72 weeks:
Bone and chemokine markers (DPD, NTX, CTX, TRACP, BAP, osteocalcin, MIP-1alpha, MIP-1beta and RANTES)
Dual-energy X-ray absorptiometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of the treatment efficacy</measure>
    <time_frame>72 weeks</time_frame>
    <description>Evaluate overall HIV management status over time with:
Other infections: HBV, HCV, RPR, TPHA
HIV treatment markers: CD4, CD8, CD4/CD8, HIV-RNA
HAART regimens and start dates
Other medications: antibiotics, anticoagulants, antiplatelets, NSAID, steroids
Past medical history
HIV risk behaviors, age, sex</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">16</enrollment>
  <condition>HIV Infections</condition>
  <condition>AIDS</condition>
  <arm_group>
    <arm_group_label>Maraviroc</arm_group_label>
    <description>Those whose take maraviroc as a part of their HIV treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No maraviroc</arm_group_label>
    <description>Those who do not take maraviroc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc</intervention_name>
    <description>Maraviroc, 300mg BID for 72 weeks, except for cases with Efavirenz or Etravirine, 600mg BID for 72 weeks</description>
    <arm_group_label>Maraviroc</arm_group_label>
    <other_name>Selzentry, or Celsentri</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood serum, blood plasma, urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Treatment group: primary care clinic, Non-treatment group: primary care clinic and
        community sample
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: Outpatients or inpatients that are treated for HIV infection at AIDS
        Clinical Center of National Center for Global Health and Medicine who meet all criteria
        following:

          -  Those whose primary care physician acknowledged the necessity of maraviroc treatment
             due to multi-resistance HIV strain that is confirmed to have CCR5 tropism.

          -  Those who are willing and able to consent to this study

          -  20 years old or older

        Exclusion Criteria: Cases applicable to ANY condition of the following:

          -  Those who are not suited for maraviroc (whose HIV strain to be CXCR4 tropism)

          -  Others who the principle investigator physician considered to be excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenji Yamamoto, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vice Director-General of Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Center for Global Health and Medicine</name>
      <address>
        <city>Shinjuku</city>
        <state>Tokyo</state>
        <zip>1628655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2011</study_first_submitted>
  <study_first_submitted_qc>September 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2011</study_first_posted>
  <last_update_submitted>September 24, 2014</last_update_submitted>
  <last_update_submitted_qc>September 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>maraviroc</keyword>
  <keyword>osteoclasts</keyword>
  <keyword>Receptors, CCR5</keyword>
  <keyword>Chemokine CCL5</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

